Connetics makes skin care cosmetically elegant.
A formulation team at Connetics Australia has developed a broad platform of technologies for creating unique and cosmetically elegant means for delivering clinically effective medications to the skin, notes a company spokesman. At its Center for Skin Biology in Palo Alto Connetics scientists unite the scientific understanding of skin diseases and drug action to develop improved treatments, he says.
Novel, topical drug formulations are assessed for pharmacological activity and screened for safety using state-of-the-art tissue culture technology. Using human skin samples, the company's scientists strive to optimize the skin penetration of drug formulations.
"Together, the Center for Skin Biology and Connetics Australia provide Connetics with a strategic and competitive advantage in the development of prescription dermatology products," says Lincoln Krochmal, executive vice president of research and development for Connetics.
The company's clinical development and regulatory expertise have enabled Connetics to obtain approval for three dermatological products formulated in the patented VersaFoam delivery vehicle. "VersaFoam--the proprietary foam delivery system used in OLUX foam, Luxq foam and Evoclin foam--offers significant advantages over conventional vehicles for the treatment of dermatological diseases," says Krochmal.
The foam formulation liquefies when applied to the skin and penetrates rapidly, leaving minimal residue and no stains or odor. "We believe the cosmetic elegance of the foam increases patient satisfaction and hence improves patient compliance," remarks Krochmal.
In market research sponsored by Connetics, more than 80% of patients said they preferred the foam to other topical delivery vehicles.
Connetics products are well supported by a comprehensive commercial team. Connetics has a professional sales force of about 200 representatives calling on dermatologists and pediatricians. Connetics' dermatology division sales force works directly with the physicians who write 90% of the dermatology prescriptions in the United States. An independent ranking of dermatology company sales forces recently placed Connetics among the industry leaders, notably No. 4 in quality.
"Our sales representatives strive to cultivate relationships of trust and confidence with the health care professionals they call on by providing balanced product information," says Greg Vontz, Connetics' president and chief operating officer. "Connetics' relationships with dermatologists and pediatricians provide the company a window into what patients and physicians expect from dermatology products as well as the challenges faced by patients with skin disease. The goal is simple: to improve the lives of patients.
"Connetics combines innovative products with superior service, information and support for dermatologists and pediatricians."
Currently marketed products include:
* OLUX (clobetasol propionate) foam, 0.05%, which delivers "a superpotent topical" corticosteroid, clobetasol propionate. OLUX is indicated for short-term topical treatment of the inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp, and for short-term topical treatment of mild to moderate plaque-type psoriasis of nonscalp regions, excluding the face and intertriginous areas.
* Luxq (betamethasone valerate) foam, 0.12%, which delivers the midpotency topical corticosteroid betamethasone valerate. Luxq is indicated for topical application in the treatment of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses of the scalp.
* Evoclin (clindamycin phosphate) foam, 1%, which delivers the topical antibiotic clindamycin phosphate. Evoclin is indicated for topical application in the treatment of acne vulgaris.
* Soriatane (acitretin) capsules, a once-a-day oral medication available in 10-mg and 25-mg capsules approved for treatment of severe psoriasis (body surface area greater than 10%) in adults. It has an established safety and efficacy profile and has been studied in five types of psoriasis: plaque, guttate, erythrodermic, pustular and palmar-plantar.
3160 Porter Dr.
Palo Alto, Calif. 94304
Key contact: Bob Lederer, Vice President of Strategic Distribution
Web site: connetics.com
Phone: (650) 843-2800
Fax: (650) 843-2899
Primary business: HEALTH CARE Dermatology
|Printer friendly Cite/link Email Feedback|
|Title Annotation:||Marketplace 2006/Corporate Profiles|
|Publication:||Chain Drug Review|
|Date:||Jun 26, 2006|
|Previous Article:||Novartis gains critical mass in O-T-C market.|
|Next Article:||RMX turns retail merchandising into an art.|